Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 trial of an RBD SARS-CoV-2 HBsAg VLP vaccine in healthy adults
ACTRN12620000817943Phase 2Recruiting
- Sponsor
- Accelagen
- Start
- Aug 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of RBD SARS-CoV-2 HBsAg VLP COVID-19 vaccine in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Accelagen. Started Aug 2020; status: recruiting.
02
Drugs
RBD SARS-CoV-2 HBsAg VLP COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620000817943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000817943.